Menopause + MHT Flashcards

1
Q

What happens to the hormones in menopause?

A

Dec in oestrogen secretion by ovarian follicular unit –> inc gonadotrophins (LH and FSH from anterior pituitary

Remaining follicles are insensitive to FSH and LH

Perimenopause = beginning of missed cycles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is perimenopause?

A

Transition before menopause (last 5 yrs)

physical and emotional changes, periods become irregular (heavy, long, or irregular)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is menopause?

A

Permanent cessation of menstruation = all ovarian follicles depleted and ovarian oestrogen production ceases

Clinical = absence of menses for at least 12 consecutive months

Factors influencing symptoms = genetic predisposition, ovarian cystectomies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What does drug therapy for menopause aim to do? (general)

A

Treat:
- vasomotor symptoms
- vaginal dryness
- dyspareunia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Discuss menopausal vasomotor instability symptoms

A

Hot flush (75-85%) = directly proportional to drop in oestrogen - red face/neck, inc skin temp, inc heart rate

Nausea, dizziness, headache, palpitation

Formication

Common in last 12-24 of menstrual period

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How is menopausal vasomotor instability treated?

A

W/ menopausal hormonal therapy (MHT)

Systemic estrogen –> best treatment for hot flushes
Intravaginal oestrogen –> less effective for hot flushes

Alternatively = clonidine –> menopausal flushing, use limited by ADRs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is used to treat menopausal vasomotor instability if MHT is C/I?

A

Antidepressants, gabapentin = limited evidence that short term low dose treatment does anything to reduce hot flushes

Low dose SSRIs or SNRIs = short trials showed reduction in number/severity of hot flushes —> venlafaxine and paroxetine more effective

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Discuss vaginal atrophy due to menopause

A

Oestrogen receptors in vagina, vulva, urethra –> des oestrogen –> atrophy of tissue

Physiological changes:
- dec subcutaneous fat and elasticity
- paleness and thinning of vaginal epithelium –> reduced secretion, distensibility

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the symptoms of menopause vaginal atrophy?

A

Vaginal dryness

Pruritus, tears or bleeding, painful urination

painful sexual intercourse

Alkalinisation of vaginal pH –> more infections

Worsen with age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the treatments for vaginal atrophy due to menopause?

A

Systemic MHT = for those w/ systemic symptoms

Intravaginal oestrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Discuss menopausal urethral syndrome and its symptoms

A

Oestrogen receptors in trigone of bladder –> tissue atrophy and loss of pelvic tone

Symptoms = stress incontinence, urge incontinence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How is menopausal urethral syndrome treated?

A

Pelvic floor exercises
Systemic MHT
Intravaginal oestrogen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the risk factors to osteoporosis?

A

Slender, sedentary females
Caucasian or Asian descent
Smoking/alcohol use
Low intake of calcium and vitamin D
family history
Chronic steroid use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the treatment for CHD in menopausal women (pharm and lifestyle)?

A

Diet, exercise, +/- pharm drug therapy (lipid lowering agents)

Control of complications = diabetes, HTN, hypercholesterolaemia

Smoking cessation, moderation in alcohol consumption, stress reduction

Oestrogen replacement therapy (ERT) = inc HDL, dec LDL (transdermal oestrogen no effect here)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What effect would combined MHT have on menopausal CHD risk?

A

May attenuate or eliminate benefit on HDL cholesterol

Therapy limited to low doses, reserved for those w/ intact uterus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What tests should be conduction prior to menopausal treatment?

A

Full gynaecological hx and examination (breast, cervical, pelvis)

Mammography (>50 years of age)

blood pressure, blood lipids

complete blood examination

Thyroid stimulating hormone

bone density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are some cancer risks with menopausal hormone therapy (MHT)?

A

Incidence of breast cancer inc w/ age

- Oral/transdermal inc breast cancer risk --> associated w/ duration of use, lower risk w/ cyclical treatment
- Low dose vaginal oestrogen does not inc risk of breast cancer

Endometrial cancer (oestrogen only MHT)
- reduce risk w/ progestogen at least 10 days/month

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are additional risks associated w/ menopause hormone therapy?

A

Both oestrogen + combined therapy = Coronary heart disease (combined mostly), VTE (combined therapy), Stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are C/I to systemic menopausal hormone therapy?

A

Aged >60 yrs

Previous or active thromboembolic disorder

Unexplained uterine bleeding

Severe liver disease

uncontrolled HTN

Breast cancer or other oestrogen dependent tumour

Cerebrovascular or coronary artery disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the role of oestrogen in MHT?

A

Relieves reduced oestrogen symptoms

Estriol, estradiol, conjugated equine estrogens

21
Q

What is the role tibolone in MHT?

A

Relief menopause symptoms + prevent post-menopausal osteoporosis (in high fract risk + Tx inappropriate)

- Oestrogenic on vagina, bone, thermoreg
- Progestogenic/anti-estrogen on breast/endometrium 
- Androgenic effects = dec HDL, TG, Lipoprotein A
22
Q

What is the role of progestogens in MHT?

A

Supportive role = uterine protection (dec unopposed oestrogen cancer), contraceptive cover, suppression of menstrual cycle

Medroxyprogesterone, norethisterone, dydrogesterone

23
Q

Discuss the benefits of oral routes of MHT administration

A

Inexpensive, convenient, well tolerated

risk ADRs

24
Q

Discuss the benefits of transdermal routes of MHT administration

A

Avoid first pass effect allows smaller doses –> reduce ADRs

Risk of VTE or stroke lower, can cause skin irritation

25
Q

Discuss generally vaginal preparation routes of MHT

A

First choice for urogenital symptoms, few ADRs

Recommended that treatment is stopped at least annually

Progestogen not necessary for endometrial protection

Irregular/atypical bleeding may indicate endometrial pathology

26
Q

Discuss the use of estrogen only MHT

A

Recommended post-hysterectomy w/ no endometriosis hx (endo can still cause hyperplasia/endo cancer)

estrogen is continious

27
Q

What is conjugated equine estrogens?

A

Oestrogen derived from a pregnant mare’s urine

28
Q

Discuss the use of intravaginal oestrogen

A

local oestrogen therapy for predominantly genitourinary symptoms (dysuria, urinary freq, vaginal atrophy)

also for those where systemic treatment C/I

Need a 12 day course of progestin every 6-12 months –> reduce cancer risk

29
Q

What risks should be considered with intravaginal oestrogen?

A

Some systemic absorption can occur, safety can’t be guaranteed

Estradiol has more sig effect on serum estrogen concentration than estriol

women w/ vaginal dryness w/ hx of breast cancer should try non-hormonal preparations first

30
Q

When should combined MHT be used?

A

Women with intact uterus, contains both progestogen and estrogen

May be cyclical or continues and prevents risk of endometrial hyperplasia

Considered if hx of endo

31
Q

Discuss the use of progestogens in MHT

A

May be combined or dosed separately

reduces endometrial cancer risk associated w/ unopposed oestrogen

Micronised progesterone
Norethisterone
medroxyprogesterone
dydrogesterone (only in combination)

32
Q

Discuss the use (guidelines, process) for combined cyclical MHT regimen

A

Indicated for perimenopausal or early postmenopausal women, use until 12-18 months after last menses

Cont. oestrogen, plus progestogen for at least 10-14 days/month or 14 days/3months

W/drawal bleed after progestogen stops

33
Q

What is an alternative to combined cyclical MHT regimens for <50 years?

A

low dose COC

Symptoms may occur during pill free week

34
Q

Discussed continuous combined MHT regimens

A

Continuous oestrogen plus continuous progestogen = half or quarter of cyclic dose

Stimulate endometrium less (less hyperplasia) than sequential/unopposed oestrogen

No scheduled bleed = 50% bleed irregularly in first 6 months, 90% amenorrhoeic after 12 months

35
Q

What is typically in continuous combined MHT? (active ingredient)

A

Estradiol 1 mg +:

Dydrogesterone, norethisterone

36
Q

What are the C/I for tibolone use in MHT?

A

Breast cancer, hormone-dependent cancer

SLE, coronary artery disease

cerebrovascular disease

VTE, severe liver disease

Avoid use in >70yrs of age

avoid in inc stroke risk = HTN, diabetes, smoking, AF

37
Q

What are the estrogen related ADRs of MHT?

A

Breast enlargement/tenderness
Fluid retention
Headache
Leg cramps
Nausea

38
Q

How are estrogen related ADRs of MHT managed?

A

Reduce dose
changing the oestrogen
change the route
taking w/ food or at night = reduce nausea

39
Q

What are the progestogen related ADRs of MHT?

A

Breast enlargement/tenderness
Fluid retention
Headache
depression
PMS-like syndrome
Acne

40
Q

How are progestogen related ADRs of MHT managed?

A

Changing the progestogen

Reduce dose (Ensure endometrium protected)

changing the route

reduce duration of progestogen to 10days/month

Changing to a 3monthly cyclical regimen

Changing to continuous combined MHT if postmenopausal

41
Q

List alternative menopausal drugs/regimens

A

SERMs
Raloxifene
Testosterone cream

42
Q

Discuss the use of Raloxifene in menopause treatment

A

Estrogen agonist - bone (inc BMD, dec vert fractures), lipoprotein metabolism

Estrogen antagonist - uterine and breast tissue

Used in postmenopausal osteoporosis and prevention of breast cancer in high risk postmenopausal women

43
Q

What is raloxifene unable to do?

A

Not stimulate endometrium

No effect on vasomotor symptoms

44
Q

Discuss the use of SERM in menopause management

A

Indicated for moderate to severe vasomotor symptoms in women w/ intact uterus

Bazedoxifene = inhibit stim effects of oestrogen on endometrium, reduce risk of endometrial cancer

Reserved for women who cannot take estrogen/progestogen combinations

45
Q

What is SERM?

A

Conjugated oestrogen/bazedoxifene

46
Q

Discuss the use of testosterone cream in menopause treatment/management?

A

Used as adjunct to MHT, direct androgenic effect = takes 4-8 wks for benefit

Indication = postmenopausal women w/ low libido w/ associated distress (hypoactive sexual desire dysfunction)

ADRs = acne, inc body hair, weight gain

47
Q

Outline some practice points for MHT

A

no difference in recurrence of vasomotor symptoms between gradual and abrupt MHT w/drawal

No benefit to reduction in risk of CVD

No contraceptive protection, does not treat chronic illness

oestrogen dose used in MHT 5-6 times less than that of COCs

48
Q

What are the alternative treatments for vaginal atrophy?

A

Moisturisers = moisturise vagina (replens, aci-jels, vagisil)

Vaginal acidifiers = aci-jel (glacial acetic acid, hydroxyquinoline, ricinoleic acid), multi- gyn active gel (lowers pH, from plant extract), vagicare (ascorbic acid pessaries)

49
Q

List some CAMs for menopause

A

Black cohosh

Phyto-estrogens

Dong quai

Wild yam, natural progesterone cream

Bio-identical hormone therapies

no evidence for many of these